#### Edgar Filing: LIGAND PHARMACEUTICALS INC - Form 4

LIGAND PHARMACEUTICALS INC Form 4 November 20, 2013 FORM 4

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION OMB Washington, D.C. 20549 Number: Check this box

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction

(Print or Type Responses)

if no longer

Section 16.

Form 4 or

Form 5

1(b).

subject to

1. Name and A KOZARICI	Address of Reporting Person <u>*</u> H JOHN W	2. Issuer Name <b>and</b> Ticker or Trading Symbol LIGAND PHARMACEUTICALS INC [LGND]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
(Last) 11119 NOR ROAD, SU	(First) (Middle) ATH TORREY PINES ITE 200	3. Date of Earliest Transaction (Month/Day/Year) 11/18/2013	X_ Director 10% Owner Officer (give title Other (specify below) below)					
	(Street)	4. If Amendment, Date Original	6. Individual or Joint/Group Filing(Check					
LA JOLLA		Filed(Month/Day/Year)	Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip) <b>Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned</b>								
1.Title of	2. Transaction Date 2A. D	eemed 3. 4. Securities Acquir	ed 5. Amount of 6. Ownership 7. Nature of					
Security (Instr. 3)	any	tion Date, if Transaction(A) or Disposed of Code (Instr. 3, 4 and 5) h/Day/Year) (Instr. 8) (A) or Code V Amount (D) Pr	-					
Common Stock	11/18/2013	M 460 A <sup>\$</sup> 14	86 41,726 D					

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

**OMB APPROVAL** 

Expires:

response...

Estimated average

burden hours per

3235-0287

January 31,

2005

0.5

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Nun onof Deriva Securi Acqui (A) or Dispo of (D) (Instr. and 5)	ative ities ired r osed ) . 3, 4,	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	\$ 14.86	11/18/2013	11/18/2013	М		460	<u>(1)</u>	01/02/2014	Common Stock	460

### Edgar Filing: LIGAND PHARMACEUTICALS INC - Form 4

## **Reporting Owners**

Reporting Owner Name / Address		Relationships						
	Director	10% Owner	Officer	Other				
KOZARICH JOHN W 11119 NORTH TORREY PINES ROAD, SUITE 200 LA JOLLA, CA 92037	) X							
Signatures								
By: Charles S. Berkman For: John W. Kozarich	11/20/2013							
**Signature of Reporting Person	Date							
Explanation of Responses:								

# iation of nesponses.

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The option becomes exercisable in twelve successive equal monthly installments upon completion of each calendar month of service (1) beginning 1/31/04.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.